AUPH vs. MRUS, RYTM, AKRO, RNA, PTCT, CYTK, SRPT, KRYS, ACAD, and SWTX
Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Merus (MRUS), Rhythm Pharmaceuticals (RYTM), Akero Therapeutics (AKRO), Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Sarepta Therapeutics (SRPT), Krystal Biotech (KRYS), ACADIA Pharmaceuticals (ACAD), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry.
Aurinia Pharmaceuticals vs. Its Competitors
Merus (NASDAQ:MRUS) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
Aurinia Pharmaceuticals has a net margin of -10.23% compared to Merus' net margin of -680.61%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Merus' return on equity.
96.1% of Merus shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 4.6% of Merus shares are owned by insiders. Comparatively, 12.2% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Merus. MarketBeat recorded 9 mentions for Aurinia Pharmaceuticals and 6 mentions for Merus. Aurinia Pharmaceuticals' average media sentiment score of 1.63 beat Merus' score of 0.74 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the news media.
Merus has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Aurinia Pharmaceuticals received 210 more outperform votes than Merus when rated by MarketBeat users. Likewise, 73.41% of users gave Aurinia Pharmaceuticals an outperform vote while only 67.96% of users gave Merus an outperform vote.
Merus presently has a consensus target price of $85.83, suggesting a potential upside of 54.96%. Aurinia Pharmaceuticals has a consensus target price of $11.50, suggesting a potential upside of 39.73%. Given Merus' stronger consensus rating and higher probable upside, research analysts clearly believe Merus is more favorable than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Aurinia Pharmaceuticals beats Merus on 12 of the 19 factors compared between the two stocks.
Get Aurinia Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurinia Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AUPH) was last updated on 6/12/2025 by MarketBeat.com Staff
